Roquefort Therapeutics PLC (LSE:ROQ) (Roquefort Therapeutics PLC (LSE:ROQ)) joined Proactive London to discuss its acquisition of Oncogeni and £1mln of new funding.
Newly appointed CEO, Ajan Reginald, told Chris Rhodes of the plans for the money and the work now underway with Oncogeni.
Working on cutting-edge treatments for hard-to-treat cancers, Reginald said the new acquisition and its expertise in drugs and rolling out treatments would substantially enhance its existing portfolio.
#Roquefort Therapeutics #Oncomgeni #AIM #Cancer